Table 2.
Lipid-based nanoformulation
Diseases | Antiviral drug | Type of nanodelivery system | Lipid/polymer used as carrier | Key findings | Ref |
---|---|---|---|---|---|
HIV | Stavudine | Gelatin liposomes | Soya lecithin, gelatin |
Improves targeting to a reservoir site Controls residual viremia |
[69] |
VZV, diseases caused by herpes zoster, herpes simplex virus | Acyclovir | Solid lipid nanoparticles | Compritol 888 ATO and soya lecithin | Improve transdermal delivery | [70] |
Conjunctival, corneal, and intraocular infections and retinitis | Acyclovir | Solid lipid nanoparticles | Stearic acid, Cithrol GMS, Compritol | Improve ocular delivery | [71] |
HIV | Efavirenz | Solid lipid nanoparticles | Glyceryl monostearate, Tween 80 | Enhances solubility | [72] |
HIV | Lopinavir | SLN | Stearic acid | High LPV accumulation in lymphoidal organs | [73]. |
HIV, herpes infection | Acyclovir | Nanostructured lipid carrier | Compritol®888 ATO, Lauroglycol™ 90, Capryol™ 90, Tween® 40 | Increased permeation | [74] |
HIV | Indinavir | Lipid nanoemulsion | Cholesterol, Tween 80 | Improved drug permeability | [62] |
HIV | Saquinavir | Nanoemulsion | Lipoid®-80 |
Improved bioavailability Higher amount of the drug was able to reach the brain |
[61] |
Herpes infection | Acyclovir palmitate | Reconstituted HDL acyclovir palmitate | Phosphatidylcholin, sodium deoxycholate | High liver targeting property | [75] |